BACKGROUND: Primary biliary cirrhosis (PBC) is a liver disease of unknown etiology, whose occurrence varies greatly between different regions. For a long time there have been no published data about the incidence and prevalence of PBC from Eastern Europe countries. METHODS: The incidence and prevalence of PBC have been investigated in the Estonian population during the period 1973-92. Two sources of information were used: an information circular/questionnaire was sent to all district hospitals and gastroenterologists, and the case histories of all patients with a positive antimitochondrial antibody titer of 1:40 or more were reexamined. RESULTS: During this period 69 cases of PBC were diagnosed. The male to female ratio was 1:22; 13% of the patients were asymptomatic. The mean annual incidence was 2.27 per million, and on 31 December 1992 the point prevalence was 26.9 per million. There were differences in prevalence among the various districts of Estonia. Associated autoimmune conditions were reported in 32% of the patients. Mean survival from the time of diagnosis was 52.5 months. CONCLUSIONS: The incidence of PBC in Estonia is at the lower end of the range reported in the world literature. This has probably partly been caused by a low percentage of asymptomatic and male patients.
BACKGROUND:Primary biliary cirrhosis (PBC) is a liver disease of unknown etiology, whose occurrence varies greatly between different regions. For a long time there have been no published data about the incidence and prevalence of PBC from Eastern Europe countries. METHODS: The incidence and prevalence of PBC have been investigated in the Estonian population during the period 1973-92. Two sources of information were used: an information circular/questionnaire was sent to all district hospitals and gastroenterologists, and the case histories of all patients with a positive antimitochondrial antibody titer of 1:40 or more were reexamined. RESULTS: During this period 69 cases of PBC were diagnosed. The male to female ratio was 1:22; 13% of the patients were asymptomatic. The mean annual incidence was 2.27 per million, and on 31 December 1992 the point prevalence was 26.9 per million. There were differences in prevalence among the various districts of Estonia. Associated autoimmune conditions were reported in 32% of the patients. Mean survival from the time of diagnosis was 52.5 months. CONCLUSIONS: The incidence of PBC in Estonia is at the lower end of the range reported in the world literature. This has probably partly been caused by a low percentage of asymptomatic and male patients.
Authors: J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams Journal: Gut Date: 2007-02 Impact factor: 23.059
Authors: Robert P Myers; Abdel Aziz M Shaheen; Andrew Fong; Alex F Wan; Mark G Swain; Robert J Hilsden; Lloyd Sutherland; Hude Quan Journal: Can J Gastroenterol Date: 2010-03 Impact factor: 3.522
Authors: Andrea Crosignani; Pier-Maria Battezzati; Pietro Invernizzi; Carlo Selmi; Elena Prina; Mauro Podda Journal: World J Gastroenterol Date: 2008-06-07 Impact factor: 5.742
Authors: Carlo Selmi; Anna Maria Papini; Piera Pugliese; Maria Claudia Alcaro; M Eric Gershwin Journal: Arch Med Sci Date: 2011-07-11 Impact factor: 3.318
Authors: Jakub Gazda; Martin Janicko; Sylvia Drazilova; Ivica Grgurevic; Tajana Filipec Kanizaj; Tomas Koller; Beatrica Bodorovska; Maja Mijic; Ivana Mikolasevic; Ivana Knezevic Stromar; Branislav Kucinsky; Matej Gazda; Peter Jarcuska Journal: Can J Gastroenterol Hepatol Date: 2021-06-22
Authors: Ana Lleo; Peter Jepsen; Emanuela Morenghi; Marco Carbone; Luca Moroni; Pier Maria Battezzati; Mauro Podda; Ian R Mackay; M Eric Gershwin; Pietro Invernizzi Journal: Sci Rep Date: 2016-05-19 Impact factor: 4.379